DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
One Montvale			DATE(S) OF INSPECTION 7/24/2019-8/15/2019*		
Stoneham, MA (781)587-7500	02180 0 Fax: (781)587-7556		FEI NUMBER 3009424796		
Christopher C	rtowном REPORT ISSUED J. Breault, Chief Operating O	fficer	•		
FIRM NAME Kelyniam Glob	lobal, Inc. 97 River Rd				
COllingville	CT 06019-3246	TYPE ESTABLISHMENT INSPECTED Medical Device Manufacturer			
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.					
The observations noted in this Form FDA-483 are not an exhaustive listing of objectionable conditions. Under the law, your firm is responsible for conducting internal self-audits to identify and correct any and all violations of the quality system requirements.					
DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 Procedures to control environmental conditions have not been established. Specifically, A) The manufacture of cranial and craniofacial implants is in close-proximity to the cleaning process for these devices and in the same room, and visible particulates were observed in both the manufacturing and cleaning area during the inspection of this room. For example, during manufacture of the cranial implant, an employee was observed placing tools and (b) (4) then placing a cleaned implant, CSI020619-JB2, directly on the tray to dry. While the implant was drying, the employee (b) (4) that was filled with manufacturing particulates. B) (b) (4) has not occurred to evaluate the environmental conditions of the manufacturing/cleaning room and there are no controls in place to ensure that the cleaning area stays free of particulates that may affect the (b) (4)					
C) Your firm has (b) (4) . There are no procedures regarding the proper sequence					
of gowning and the proper use of gloves to handle cranial implants.					
AMENDMENT 1					
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Jeffrey J Thibodeau, Investi	igator		Jeffrey J Th bodeau Interest pater Signed By Jeffrey J Thibodeau - S Date Signed 08-15-2019 13 35 35	DATE ISSUED 8/15/2019

INSPECTIONAL OBSERVATIONS

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

PAGE 1 of 4 PAGES

		TH AND HUMAN SERVICE G ADMINISTRATION	ES	
DISTRICT ADDRESS AND PHON	ONE NUMBER		DATE(S) OF INSPECTION	
One Montvale		7/24/20	7/24/2019-8/15/2019*	
Stoneham, MA			3009424796	
(761) 567-7500	0 Fax: (781) 587-7556			
NAME AND TITLE OF INDIVIDUA	AL TO WHOM REPORT ISSUED	I		
Christopher d	J. Breault, Chief Operating O	fficer		
FIRM NAME		STREET ADDRESS		
Kelyniam Glok		97 River Rd		
	TRY , CT 06019-3246	TYPE ESTABLISHMENT INSPECTED Medical Device Manufacturer		
performed to ve	manufacture of implant CSI020619 erify that the device (b) (4) ation outlined in QSP4-4240 (b) (4)	_	ction was observe required by your	_
Specifically, yo	ON 2 acceptance of incoming product have ur firm's specification for (b) (4) cillofacial implants was not establish		y established. used in the manu	nfacture of
of (b) (4) your firm's spectates that implated without routine	eification, (b) (4)	to m Supplier of(b) (4)	or lot 58499526 of anufacture cranial stated that	. The NCR (b) (4) implants this
adequately valid	ON 3 e results cannot be fully verified by dated according to established process cleaning validation for cranial and atside of bacterial endotoxins.	edures.		
*DATES OF I	NSPECTION			
AMENDMENT 1				
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Jeffrey J Thibodeau, Invest	igator	Jeffrey J Th bodeau Investigator Jeffrey J. Thibodeau -S Signed by Jeffrey J. Thibodeau -S Date Signed 08-15-2019 13 35 35	DATE ISSUED 8/15/2019
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE INS	SPECTIONAL OBSERVATIONAL	ONS	PAGE 2 of 4 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHON	IE NUMBER	DATE(S) OF	INSPECTION 2019-8/15/2019*	
Stoneham, MA			FEI NUMBER	
(781) 587-7500	Fax: (781) 587-7556	30094	24796	
NAME AND TITLE OF INDIVIDUA	AL TO WHOM REPORT ISSUED	I		
_	J. Breault, Chief Operating			
FIRM NAME				
Collinsville,	, CT 06019-3246 Medical Device Manufacturer			
	AME	NDMENT 1		
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Jeffrey J Thibodeau, Invest	igator	Jeffrey J Th bodeau Investigator Investigator Entry J Thibodeau -S Date signed 08-15-2019 13 35 35	DATE ISSUED 8/15/2019
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE IN	SPECTIONAL OBSERVA	TIONS	PAGE 3 of 4 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES					
DISTRICT ADDRESS AND PHO		OD AND DRUG ADMINISTRAT	TON DATE(S) OF INSPECTION		
One Montvale			7/24/2019-8/15/2019*		
Stoneham, MA			FEI NUMBER		
	Fax: (781) 587-7556		3009424796		
NAME AND TITLE OF INDIVIDUA		+: Off:			
Christopher o	J. Breault, Chief Oper	_			
	1 T	STREET ADDRESS			
Kelyniam Glo		97 River			
	, CT 06019-3246	l l	TYPE ESTABLISHMENT INSPECTED Medical Device Manufacturer		
Annotations to	Observations				
Observation 1:					
Observation 2:					
Observation 3:					
		AMENDMENT 1			
	EMPLOYEE(C) CIONATURE			DATE INC. IEE	
SEE REVERSE	Jeffrey J Thibodeau,	Investigator	1	8/15/2019	
OF THIS PAGE	Jerrie y O Inibodeau,	TITVESCIGATOI	Jeffrey J Th bodeau	0/13/2019	
JI IIIIO FAGE			Investigator Signed By Jeffrey J. Thibodeau -S Date Signed 08-15-2019 13 35 35		
			^ -		
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL O	OBSERVATIONS	PAGE 4 of 4 PAGES	

The observations of objectionable conditions and practices listed on the front of this form are reported:

- 1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or
- 2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.

Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides:

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."